ZHANG, Qian; PIZZORNO, Andres; MIORIN, Lisa; BASTARD, Paul; GERVAIS, Adrian; LE VOYER, Tom; BIZIEN, Lucy; MANRY, Jeremy; ROSAIN, Jeremie; PHILIPPOT, Quentin; GOAVEC, Kelian; PADEY, Blandine; CUPIC, Anastasija; LAURENT, Emilie; SAKER, Kahina; VANKER, Martti; SAREKANNU, Karita; GARCIA-SALUM, Tamara; FERRES, Marcela; LE CORRE, Nicole; SANCHEZ-CESPEDES, Javier; BALSERA-MANZANERO, Maria; CARRATALA, Jordi; RETAMAR-GENTIL, Pilar; ABELENDA-ALONSO, Gabriela; VALIENTE, Adoracion; TIBERGHIEN, Pierre; ZINS, Marie; DEBETTE, Stephanie; MEYTS, Isabelle; HAERYNCK, Filomeen; CASTAGNOLI, Riccardo; NOTARANGELO, Luigi D.; GONZALEZ-GRANADO, Luis I.; DOMINGUEZ-PINILLA, Nerea; ANDREAKOS, Evangelos; TRIANTAFYLLIA, Vasiliki; RODRIGUEZ-GALLEGO, Carlos; SOLE-VIOLAN, Jordi; RUIZ-HERNANDEZ, Jose Juan; RODRIGUEZ DE CASTRO, Felipe; FERRERES, Jose; BRIONES, Marisa; WAUTERS, Joost; VANDERBEKE, Lore; FEYS, Simon; KUO, Chen-Yen; LEI, Wei-Te; KU, Cheng-Lung; TAL, Galit; ETZIONI, Amos; HANNA, Suhair; FOURNET, Thomas; CASALEGNO, Jean-Sebastien; QUEROMES, Gregory; ARGAUD, Laurent; JAVOUHEY, Etienne; ROSA-CALATRAVA, Manuel; CORDERO, Elisa; AYDILLO, Teresa; MEDINA, Rafael A.; KISAND, Kai; PUEL, Anne; JOUANGUY, Emmanuelle; ABEL, Laurent; COBAT, Aurelie; TROUILLET-ASSANT, Sophie; GARCIA-SASTRE, Adolfo; CASANOVA, Jean-Laurent

doi:10.1084/jem.20220514

Langue

Article de revue

Ce document a été publié dans

Journal of Experimental Medicine. 2022-11-07, vol. 219, n° 11

Résumé en anglais

Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-α2 alone (five patients) or with IFN-ω (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-α2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-ω. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients <70 yr of age (5.7 vs. 1.1%, P = 2.2 × 10-5), but not >70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-α2 and IFN-ω (OR = 11.7, P = 1.3 × 10-5), especially those <70 yr old (OR = 139.9, P = 3.1 × 10-10). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for ∼5% of cases of life-threatening influenza pneumonia in patients <70 yr old.< Réduire

URI

https://oskar-bordeaux.fr/handle/20.500.12278/171566

DOI

http://dx.doi.org/10.1084/jem.20220514

Project ANR

Institut Hospitalo-Universitaire Imagine
Integrative Biology of Emerging Infectious Diseases
Covid-19 and interferons: from discovery to therapy
Analyse multi-omique de l'immunité anti-virale: de l'identification des circuits biologiques pertinents à la découverte de défauts monogéniques héréditaires de l'immunité chez les patients avec infections virales sévères
Recherche des Déficits immunitaires innées monogéniques prédisposant au syndrome inflammatoire multisystémique chez l'enfant. - ANR-21-COVR-0039
Bases génétiques et immunologiques des auto-anticorps contre les interférons de type I prédisposant aux formes sévères de COVID-19.

Unités de recherche

Bordeaux Population Health Research Center (BPH) - UMR 1219

Voir/Ouvrir

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Autoantibodies against type I IFNs in patients with critical influenza pneumonia

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Project ANR

Unités de recherche